© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 16, 1295-1302,
August 16, 2000
© 2000 Oxford University Press
REVIEW |
A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins
Affiliation of authors: Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam.
Correspondence to: Piet Borst, M.D., Ph.D., Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands (e-mail: pborst{at}nki.nl).
The human multidrug resistance-associated protein (MRP) family currently has seven members. The ability of several of these membrane proteins to transport a wide range of anticancer drugs out of cells and their presence in many tumors make them prime suspects in unexplained cases of drug resistance, although proof that they contribute to clinical drug resistance is still lacking. Recent studies have begun to clarify the function of the MRP family members. MRPs are organic anion transporters; i.e., they transport anionic drugs, exemplified by methotrexate, and neutral drugs conjugated to acidic ligands, such as glutathione (GSH), glucuronate, or sulfate. However, MRP1, MRP2, and MRP3 can also cause resistance to neutral organic drugs that are not known to be conjugated to acidic ligands by transporting these drugs together with free GSH. MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compounds in complexes with GSH. MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs. MRPs may, therefore, also have a role in resistance against nucleoside analogues used in cancer chemotherapy. Mice without Mrp1, a high-affinity leukotriene C4 transporter, have an altered response to inflammatory stimuli but are otherwise healthy and fertile. MRP2 is the major transporter responsible for the secretion of bilirubin glucuronides into bile, and humans without MRP2 develop a mild liver disease known as the Dubin–Johnson syndrome. The physiologic functions of the other MRPs are not known. Whether long-term inhibition of MRPs in humans can be tolerated (assuming that suitable inhibitors will be found) remains to be determined.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Burkhart, F. Watt, J. Murray, M. Pajic, A. Prokvolit, C. Xue, C. Flemming, J. Smith, A. Purmal, N. Isachenko, et al. Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma Cancer Res., August 15, 2009; 69(16): 6573 - 6580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Nzoughet, J. T. G. Hamilton, C. H. Botting, A. Douglas, L. Devine, J. Nelson, and C. T. Elliott Proteomics Identification of Azaspiracid Toxin Biomarkers in Blue Mussels, Mytilus edulis Mol. Cell. Proteomics, August 1, 2009; 8(8): 1811 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Raj, J. Mu, H. Jiang, J. Kabat, S. Singh, M. Sullivan, M. P. Fay, T. F. McCutchan, and X.-z. Su Disruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and Glutathione J. Biol. Chem., March 20, 2009; 284(12): 7687 - 7696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshioka, H. Sagara, F. Takahashi, N. Harada, K. Nishio, A. Mori, H. Ushio, K. Shimizu, T. Okada, M. Ota, et al. Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation Am J Physiol Lung Cell Mol Physiol, January 1, 2009; 296(1): L30 - L36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Nevala, T Ylikomi, and H Tahti Evaluation of the selected barrier properties of retinal pigment epithelial cell line ARPE-19 for an in-vitro blood-brain barrier model Human and Experimental Toxicology, October 1, 2008; 27(10): 741 - 749. [Abstract] [PDF]
|
|
|
|
 |
|
 R. van de Ven, G. L. Scheffer, A. W. Reurs, J. J. Lindenberg, R. Oerlemans, G. Jansen, J.-P. Gillet, J. N. Glasgow, A. Pereboev, D. T. Curiel, et al. A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration Blood, September 15, 2008; 112(6): 2353 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Aiba, A. Hossain, and M. T. Kuo Elevated GSH Level Increases Cadmium Resistance through Down-Regulation of Sp1-Dependent Expression of the Cadmium Transporter ZIP8 Mol. Pharmacol., September 1, 2008; 74(3): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Johnatty, J. Beesley, J. Paul, S. Fereday, A. B. Spurdle, P. M. Webb, K. Byth, S. Marsh, H. McLeod, AOCS Study Group, et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5594 - 5601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yoshida, T. Takada, Y. Yamamura, I. Adachi, H. Suzuki, and J. Kawakami Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport Drug Metab. Dispos., July 1, 2008; 36(7): 1206 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O'Brien, G. Cavet, A. Pandita, X. Hu, L. Haydu, S. Mohan, K. Toy, C. S. Rivers, Z. Modrusan, L. C. Amler, et al. Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer Cancer Res., July 1, 2008; 68(13): 5380 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lickteig, C. D. Fisher, L. M. Augustine, L. M. Aleksunes, D. G. Besselsen, A. L. Slitt, J. E. Manautou, and N. J. Cherrington Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease Drug Metab. Dispos., October 1, 2007; 35(10): 1970 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Madejczyk, D. A. Aremu, T. A. Simmons-Willis, T. W. Clarkson, and N. Ballatori Accelerated Urinary Excretion of Methylmercury following Administration of Its Antidote N-Acetylcysteine Requires Mrp2/Abcc2, the Apical Multidrug Resistance-Associated Protein J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Luo, C. E. Garner, H. Xiong, H. Hu, L. E. Richards, K. L. R. Brouwer, J. Duan, C. P. Decicco, T. Maduskuie, H. Shen, et al. Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor {alpha}-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study Drug Metab. Dispos., June 1, 2007; 35(6): 835 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lai, L. Xing, G. I. Poda, and Y. Hu Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles Drug Metab. Dispos., June 1, 2007; 35(6): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh, S. De, and S. K. Dutta Altered Protein Expressions in Chronic PCB-153-Induced Human Liver (HepG2) Cells International Journal of Toxicology, May 1, 2007; 26(3): 203 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Han, L. Li, S. Qiu, Q. Lu, Q. Pan, Y. Gu, J. Luo, and X. Hu Shikonin circumvents cancer drug resistance by induction of a necroptotic death Mol. Cancer Ther., May 1, 2007; 6(5): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neuzil, M. Tomasetti, Y. Zhao, L.-F. Dong, M. Birringer, X.-F. Wang, P. Low, K. Wu, B. A. Salvatore, and S. J. Ralph Vitamin E Analogs, a Novel Group of "Mitocans," as Anticancer Agents: The Importance of Being Redox-Silent Mol. Pharmacol., May 1, 2007; 71(5): 1185 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Deeken and W. Loscher The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses Clin. Cancer Res., March 15, 2007; 13(6): 1663 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weiss, D. Theile, N. Ketabi-Kiyanvash, H. Lindenmaier, and W. E. Haefeli Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors Drug Metab. Dispos., March 1, 2007; 35(3): 340 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Seo, E. Hatano, T. Higashi, T. Hara, M. Tada, N. Tamaki, K. Iwaisako, I. Ikai, and S. Uemoto Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baltes, M. Fedrowitz, C. L. Tortos, H. Potschka, and W. Loscher Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 331 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Wever, R. Masereeuw, D. S. Miller, X. M. Hang, and G. Flik Endothelin and calciotropic hormones share regulatory pathways in multidrug resistance protein 2-mediated transport Am J Physiol Renal Physiol, January 1, 2007; 292(1): F38 - F46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Velsor, C. Kariya, R. Kachadourian, and B. J. Day Mitochondrial Oxidative Stress in the Lungs of Cystic Fibrosis Transmembrane Conductance Regulator Protein Mutant Mice Am. J. Respir. Cell Mol. Biol., November 1, 2006; 35(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Choudhuri and C. D. Klaassen Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters International Journal of Toxicology, July 1, 2006; 25(4): 231 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dallas, D. S. Miller, and R. Bendayan Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., June 1, 2006; 58(2): 140 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van de Ven, M. C. de Jong, A. W. Reurs, A. J. N. Schoonderwoerd, G. Jansen, J. H. Hooijberg, G. L. Scheffer, T. D. de Gruijl, and R. J. Scheper Dendritic Cells Require Multidrug Resistance Protein 1 (ABCC1) Transporter Activity for Differentiation J. Immunol., May 1, 2006; 176(9): 5191 - 5198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haber, J. Smith, S. B. Bordow, C. Flemming, S. L. Cohn, W. B. London, G. M. Marshall, and M. D. Norris Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma J. Clin. Oncol., April 1, 2006; 24(10): 1546 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kis, T. Isse, J. A. Snipes, L. Chen, H. Yamashita, Y. Ueta, and D. W. Busija Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers J Appl Physiol, April 1, 2006; 100(4): 1392 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, M. A. Alston, H. Huang, and R. L. Rabin Human T cell cytokine responses are dependent on multidrug resistance protein-1 Int. Immunol., March 1, 2006; 18(3): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Remy and H. Beck Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain, January 1, 2006; 129(1): 18 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L.A. Plasschaert, E. S.J.M. de Bont, M. Boezen, D. M. vander Kolk, S. M.J.G. Daenen, K. N. Faber, W. A. Kamps, E. G.E. de Vries, and E. Vellenga Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia Clin. Cancer Res., December 15, 2005; 11(24): 8661 - 8668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ballatori Biology of a Novel Organic Solute and Steroid Transporter, OST{alpha}-OST{beta} Experimental Biology and Medicine, November 1, 2005; 230(10): 689 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Kang, E. Lee, H. Pyo, and S.-J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-f. Zhou, X. Yang, Q. Wang, R. A. Coburn, and M. E. Morris EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES Drug Metab. Dispos., August 1, 2005; 33(8): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Meyer zu Schwabedissen, G. Jedlitschky, M. Gratz, S. Haenisch, K. Linnemann, C. Fusch, I. Cascorbi, and H. K. Kroemer VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION Drug Metab. Dispos., July 1, 2005; 33(7): 896 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al. The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates Cancer Res., May 15, 2005; 65(10): 4425 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Burckhardt Polyspecific Organic Cation Transport: Insights into the Substrate Binding Site Mol. Pharmacol., May 1, 2005; 67(5): 1391 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, X. Tian, P. Chandra, and K. L. R. Brouwer Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat Hepatocytes Mol. Pharmacol., April 1, 2005; 67(4): 1334 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, and J S Smolen Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis Ann Rheum Dis, April 1, 2005; 64(4): 564 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Park and P. J. Sinko P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benlloch, A. Ortega, P. Ferrer, R. Segarra, E. Obrador, M. Asensi, J. Carretero, and J. M. Estrela Acceleration of Glutathione Efflux and Inhibition of {gamma}-Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity J. Biol. Chem., February 25, 2005; 280(8): 6950 - 6959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, R. Grill, R. Pirker, C. C. Zielinski, H. Hausmaninger, E. Kubista, et al. Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group J. Clin. Oncol., February 20, 2005; 23(6): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. M. H. Van Aubel, P. H. E. Smeets, J. J. M. W. van den Heuvel, and F. G. M. Russel Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites Am J Physiol Renal Physiol, February 1, 2005; 288(2): F327 - F333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Aleksunes, A. M. Slitt, N. J. Cherrington, M. S. Thibodeau, C. D. Klaassen, and J. E. Manautou Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon Tetrachloride Toxicol. Sci., January 1, 2005; 83(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ford, S. H. Khoo, and D. J. Back The intracellular pharmacology of antiretroviral protease inhibitors J. Antimicrob. Chemother., December 1, 2004; 54(6): 982 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Toffoli, G. Corona, G. Cattarossi, M. Boiocchi, G. Di Gennaro, U. Tirelli, and E. Vaccher Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma Ann. Onc., December 1, 2004; 15(12): 1805 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, Y. Kobayashi, T. Hayakawa, and S. Hirano Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats Toxicol. Sci., December 1, 2004; 82(2): 478 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. St-Pierre, T. Stallmach, A. Freimoser Grundschober, J.-F. Dufour, M. A. Serrano, J. J. G. Marin, Y. Sugiyama, and P. J. Meier Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1505 - R1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jedlitschky, K. Tirschmann, L. E. Lubenow, H. K. Nieuwenhuis, J. W. N. Akkerman, A. Greinacher, and H. K. Kroemer The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage Blood, December 1, 2004; 104(12): 3603 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. E. Sauna, K. Nandigama, and S. V. Ambudkar Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis: EFFECT OF TRANSPORT SUBSTRATES AND CHARACTERIZATION OF THE POST-HYDROLYSIS TRANSITION STATE J. Biol. Chem., November 19, 2004; 279(47): 48855 - 48864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, J. D. Schuetz, W. F. Elmquist, and D. W. Miller Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Situ, A. Haimeur, G. Conseil, K. E. Sparks, D. Zhang, R. G. Deeley, and S. P. C. Cole Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1): GLUTAMATE 1204 IS IMPORTANT FOR BOTH THE EXPRESSION AND CATALYTIC ACTIVITY OF THE TRANSPORTER J. Biol. Chem., September 10, 2004; 279(37): 38871 - 38880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Iohom, D. Fitzgerald, and A. J. Cunningham Principles of pharmacogenetics--implications for the anaesthetist Br. J. Anaesth., September 1, 2004; 93(3): 440 - 450. [Full Text] [PDF]
|
|
|
|
|
|
N. Morioka, K. Kumagai, K. Morita, S. Kitayama, and T. Dohi Nonsteroidal Anti-Inflammatory Drugs Potentiate 1-Methyl-4-phenylpyridinium (MPP+)-Induced Cell Death by Promoting the Intracellular Accumulation of MPP+ in PC12 Cells J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Michot, F. Van Bambeke, M.-P. Mingeot-Leclercq, and P. M. Tulkens Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2673 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ito, T. Koresawa, K. Nakano, and T. Horie Mrp2 is involved in benzylpenicillin-induced choleresis Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G42 - G49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Haimeur, G. Conseil, R. G. Deeley, and S. P.C. Cole Mutations of Charged Amino Acids in or near the Transmembrane Helices of the Second Membrane Spanning Domain Differentially Affect the Substrate Specificity and Transport Activity of the Multidrug Resistance Protein MRP1 (ABCC1) Mol. Pharmacol., June 1, 2004; 65(6): 1375 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Ozvaran, X. X. Cao, S. D. Miller, B. A. Monia, W. K. Hong, and W. R. Smythe Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma Mol. Cancer Ther., May 1, 2004; 3(5): 545 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Y. Chu, S.-E. W. Huskey, M. P. Braun, B. Sarkadi, D. C. Evans, and R. Evers Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3 J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 156 - 164. [Abstract] [Full Text]
|
|
|
|
|
|
K. Koike, G. Conseil, E. M. Leslie, R. G. Deeley, and S. P. C. Cole Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions J. Biol. Chem., March 26, 2004; 279(13): 12325 - 12336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Qiu, T. F. Kalhorn, and J. T. Slattery ABCC2-Mediated Biliary Transport of 4-Glutathionylcyclophosphamide and Its Contribution to Elimination of 4-Hydroxycyclophosphamide in Rat J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Kharasch, C. Hoffer, T. G. Altuntas, and D. Whittington Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl J. Clin. Pharmacol., March 1, 2004; 44(3): 224 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, G L Scheffer, R J Scheper, Y G Assaraf, and G Jansen Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs Ann Rheum Dis, February 1, 2004; 63(2): 131 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J van der Heijden, M C de Jong, B A C Dijkmans, W F Lems, R Oerlemans, I Kathmann, C G Schalkwijk, G L Scheffer, R J Scheper, and G Jansen Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF{alpha} Ann Rheum Dis, February 1, 2004; 63(2): 138 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Smitherman, A. J. Townsend, T. E. Kute, and C. S. Morrow Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil Cytotoxicity J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype Blood, December 15, 2003; 102(13): 4493 - 4498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Litman, T. Skovsgaard, and W. D. Stein Pumping of Drugs by P-Glycoprotein: A Two-Step Process? J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taniguchi, Y. Mochida, T. Uchiumi, T. Tahira, K. Hayashi, K. Takagi, M. Shimada, Y. Maehara, H. Kuwano, S. Kono, et al. Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon Mol. Cancer Ther., December 1, 2003; 2(12): 1351 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Vaidyanathan and T. Walle Cellular Uptake and Efflux of the Tea Flavonoid (-)Epicatechin-3-gallate in the Human Intestinal Cell Line Caco-2 J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Brooks, H. Minderman, K. L. O'Loughlin, P. Pera, I. Ojima, M. R. Baer, and R. J. Bernacki Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol. Cancer Ther., November 1, 2003; 2(11): 1195 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. de Jong, G. L. Scheffer, H. J. Broxterman, J. H. Hooijberg, J. W. Slootstra, R. H. Meloen, R. J. Kreitman, S. R. Husain, B. H. Joshi, R. K. Puri, et al. Multidrug-Resistant Tumor Cells Remain Sensitive to a Recombinant Interleukin-4-Pseudomonas Exotoxin, Except When Overexpressing the Multidrug Resistance Protein MRP1 Clin. Cancer Res., October 15, 2003; 9(13): 5009 - 5017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dazert, K. Meissner, S. Vogelgesang, B. Heydrich, L. Eckel, M. Bohm, R. Warzok, R. Kerb, U. Brinkmann, E. Schaeffeler, et al. Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human Heart Am. J. Pathol., October 1, 2003; 163(4): 1567 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Slitt, N. J. Cherrington, J. M. Maher, and C. D. Klaassen INDUCTION OF MULTIDRUG RESISTANCE PROTEIN 3 IN RAT LIVER IS ASSOCIATED WITH ALTERED VECTORIAL EXCRETION OF ACETAMINOPHEN METABOLITES Drug Metab. Dispos., September 1, 2003; 31(9): 1176 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Gallo, S. Li, P. Guo, K. Reed, and J. Ma The Effect of P-glycoprotein on Paclitaxel Brain and Brain Tumor Distribution in Mice Cancer Res., August 15, 2003; 63(16): 5114 - 5117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia Blood, August 15, 2003; 102(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, K. Ito, and T. Horie Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G602 - G610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Warner and J. A. Mitchell Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC? PNAS, August 5, 2003; 100(16): 9108 - 9110. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Seward, A. S. Koh, J. L. Boyer, and N. Ballatori Functional Complementation between a Novel Mammalian Polygenic Transport Complex and an Evolutionarily Ancient Organic Solute Transporter, OST{alpha}-OST{beta} J. Biol. Chem., July 18, 2003; 278(30): 27473 - 27482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nzila, E. Mberu, P. Bray, G. Kokwaro, P. Winstanley, K. Marsh, and S. Ward Chemosensitization of Plasmodium falciparum by Probenecid In Vitro Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2108 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schroppel and B. Murphy Gene Variants Affecting Bioavailability of Drugs: Towards Individualized Immunosuppressive Therapy? J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1955 - 1957. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schroeder, K. M. Bernt, B. Lange, J. Wenkel, J. Jikai, D. Shabat, R. Amir, N. Huebener, A. G. Niethammer, C. Hagemeier, et al. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia Blood, July 1, 2003; 102(1): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zelcer, M. T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J. H. M. Schellens, A. H. Schinkel, and P. Borst Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2) J. Biol. Chem., June 20, 2003; 278(26): 23538 - 23544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, H. Suzuki, Y. Sugimoto, and Y. Sugiyama ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics J. Biol. Chem., June 13, 2003; 278(25): 22644 - 22649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, D. P. Hartley, S. L. Ciccotto, S. H. Vincent, R. B. Franklin, and M.-S. Kim INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3 Drug Metab. Dispos., June 1, 2003; 31(6): 773 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mayer, F. Honecker, L. H. J. Looijenga, and C. Bokemeyer Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors Ann. Onc., June 1, 2003; 14(6): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S L Hider, C Morgan, E Bell, I N Bruce, P Ranganathan, and H L McLeod Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA? Ann Rheum Dis, June 1, 2003; 62(6): 591 - 591. [Full Text] [PDF]
|
|
|
|
 |
|
 W E Evans Pharmacogenomics: marshalling the human genome to individualise drug therapy Gut, May 1, 2003; 52(90002): ii10 - 18. [Abstract] [Full Text]
|
|